Ironwood Pharmaceuticals ... (IRWD)
Bid | 0.66 |
Market Cap | 106.57M |
Revenue (ttm) | 351.41M |
Net Income (ttm) | 28.33M |
EPS (ttm) | 0.01 |
PE Ratio (ttm) | 65.86 |
Forward PE | 17.88 |
Analyst | Buy |
Ask | 0.7 |
Volume | 7,971,198 |
Avg. Volume (20D) | 3,390,798 |
Open | 0.71 |
Previous Close | 0.95 |
Day's Range | 0.59 - 0.73 |
52-Week Range | 0.59 - 8.45 |
Beta | 0.30 |
About IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European...
Analyst Forecast
According to 4 analyst ratings, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 1418.37% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

1 month ago · seekingalpha.com
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call TranscriptIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Greg Martini - Chief Financial Officer Tom McCourt - Chief Executive Of...